Mesoblast Ltd's stock plummeted 8.93% during Monday's intraday trading session following a downward revision of its price target by investment firm Jefferies.
The stock decline came after Jefferies reduced its price target for Mesoblast to AU$3.20 per share from AU$3.50 per share, while maintaining a buy rating on the stock. The price target adjustment was part of a broader review of Australian healthcare stocks by the firm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.